Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation

W. F. Chiang, T. M. Cheng, C. C. Chang, S. H. Pan, C. A. Changou, T. H. Chang, K. H. Lee, S. Y. Wu, Y. F. Chen, K. H. Chuang, D. B. Shieh, Y. L. Chen, C. C. Tu, W. L. Tsui, M. H. Wu

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Aberrant protein glycosylation could be a distinct surface-marker of cancer cells that influences cancer progression and metastasis because glycosylation can regulate membrane protein folding which alters receptor activation and changes epitope exposure for antibody (Ab) recognition. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol-anchored protein, is a heavily glycosylated tumor antigen. However, the clinical significance and biological effect of CEACAM6 glycosylation has not been addressed in cancers. We recently developed an anti-CEACAM6 Ab (TMU) from an immune llama library which can be engineered to a single-domain (sd)Ab or a heavy-chain (HC)Ab. The TMU HCAb specifically recognized glycosylated CEACAM6 compared to the conventional antibodies. Using the TMU HCAb, we found that glycosylated CEACAM6 was a tumor marker associated with recurrence in early-stage OSCC (oral squamous cell carcinoma) patients. CEACAM6 promoted OSCC cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn 256 (N256) of CEACAM6. Finally, the TMU sdAb and HCAb treatment inhibited the migration, invasion and EGF-induced signaling in CEACAM6-overexpressing cells. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. Targeting glycosylated CEACAM6 with the TMU sdAb or TMU HCAb could be a feasible therapy for OSCC.
原文英語
頁(從 - 到)116-127
頁數12
期刊Oncogene
37
發行號1
DOIs
出版狀態已發佈 - 一月 4 2018

指紋

Carcinoembryonic Antigen
Cell Adhesion Molecules
Glycosylation
Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Neoplasm Metastasis
Antibodies
Oral Stage
Single-Domain Antibodies
New World Camelids
Neoplasms
Protein Folding
Neoplasm Antigens
Tumor Biomarkers
Epidermal Growth Factor
Libraries
Cell Movement
Cluster Analysis
Epitopes
Membrane Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

引用此文

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation. / Chiang, W. F.; Cheng, T. M.; Chang, C. C.; Pan, S. H.; Changou, C. A.; Chang, T. H.; Lee, K. H.; Wu, S. Y.; Chen, Y. F.; Chuang, K. H.; Shieh, D. B.; Chen, Y. L.; Tu, C. C.; Tsui, W. L.; Wu, M. H.

於: Oncogene, 卷 37, 編號 1, 04.01.2018, p. 116-127.

研究成果: 雜誌貢獻文章

@article{e0ec5b3b90ca4237a9c3278152e9b0d6,
title = "Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation",
abstract = "Aberrant protein glycosylation could be a distinct surface-marker of cancer cells that influences cancer progression and metastasis because glycosylation can regulate membrane protein folding which alters receptor activation and changes epitope exposure for antibody (Ab) recognition. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol-anchored protein, is a heavily glycosylated tumor antigen. However, the clinical significance and biological effect of CEACAM6 glycosylation has not been addressed in cancers. We recently developed an anti-CEACAM6 Ab (TMU) from an immune llama library which can be engineered to a single-domain (sd)Ab or a heavy-chain (HC)Ab. The TMU HCAb specifically recognized glycosylated CEACAM6 compared to the conventional antibodies. Using the TMU HCAb, we found that glycosylated CEACAM6 was a tumor marker associated with recurrence in early-stage OSCC (oral squamous cell carcinoma) patients. CEACAM6 promoted OSCC cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn 256 (N256) of CEACAM6. Finally, the TMU sdAb and HCAb treatment inhibited the migration, invasion and EGF-induced signaling in CEACAM6-overexpressing cells. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. Targeting glycosylated CEACAM6 with the TMU sdAb or TMU HCAb could be a feasible therapy for OSCC.",
author = "Chiang, {W. F.} and Cheng, {T. M.} and Chang, {C. C.} and Pan, {S. H.} and Changou, {C. A.} and Chang, {T. H.} and Lee, {K. H.} and Wu, {S. Y.} and Chen, {Y. F.} and Chuang, {K. H.} and Shieh, {D. B.} and Chen, {Y. L.} and Tu, {C. C.} and Tsui, {W. L.} and Wu, {M. H.}",
year = "2018",
month = "1",
day = "4",
doi = "10.1038/onc.2017.303",
language = "English",
volume = "37",
pages = "116--127",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation

AU - Chiang, W. F.

AU - Cheng, T. M.

AU - Chang, C. C.

AU - Pan, S. H.

AU - Changou, C. A.

AU - Chang, T. H.

AU - Lee, K. H.

AU - Wu, S. Y.

AU - Chen, Y. F.

AU - Chuang, K. H.

AU - Shieh, D. B.

AU - Chen, Y. L.

AU - Tu, C. C.

AU - Tsui, W. L.

AU - Wu, M. H.

PY - 2018/1/4

Y1 - 2018/1/4

N2 - Aberrant protein glycosylation could be a distinct surface-marker of cancer cells that influences cancer progression and metastasis because glycosylation can regulate membrane protein folding which alters receptor activation and changes epitope exposure for antibody (Ab) recognition. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol-anchored protein, is a heavily glycosylated tumor antigen. However, the clinical significance and biological effect of CEACAM6 glycosylation has not been addressed in cancers. We recently developed an anti-CEACAM6 Ab (TMU) from an immune llama library which can be engineered to a single-domain (sd)Ab or a heavy-chain (HC)Ab. The TMU HCAb specifically recognized glycosylated CEACAM6 compared to the conventional antibodies. Using the TMU HCAb, we found that glycosylated CEACAM6 was a tumor marker associated with recurrence in early-stage OSCC (oral squamous cell carcinoma) patients. CEACAM6 promoted OSCC cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn 256 (N256) of CEACAM6. Finally, the TMU sdAb and HCAb treatment inhibited the migration, invasion and EGF-induced signaling in CEACAM6-overexpressing cells. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. Targeting glycosylated CEACAM6 with the TMU sdAb or TMU HCAb could be a feasible therapy for OSCC.

AB - Aberrant protein glycosylation could be a distinct surface-marker of cancer cells that influences cancer progression and metastasis because glycosylation can regulate membrane protein folding which alters receptor activation and changes epitope exposure for antibody (Ab) recognition. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol-anchored protein, is a heavily glycosylated tumor antigen. However, the clinical significance and biological effect of CEACAM6 glycosylation has not been addressed in cancers. We recently developed an anti-CEACAM6 Ab (TMU) from an immune llama library which can be engineered to a single-domain (sd)Ab or a heavy-chain (HC)Ab. The TMU HCAb specifically recognized glycosylated CEACAM6 compared to the conventional antibodies. Using the TMU HCAb, we found that glycosylated CEACAM6 was a tumor marker associated with recurrence in early-stage OSCC (oral squamous cell carcinoma) patients. CEACAM6 promoted OSCC cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn 256 (N256) of CEACAM6. Finally, the TMU sdAb and HCAb treatment inhibited the migration, invasion and EGF-induced signaling in CEACAM6-overexpressing cells. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. Targeting glycosylated CEACAM6 with the TMU sdAb or TMU HCAb could be a feasible therapy for OSCC.

UR - http://www.scopus.com/inward/record.url?scp=85040165312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040165312&partnerID=8YFLogxK

U2 - 10.1038/onc.2017.303

DO - 10.1038/onc.2017.303

M3 - Article

VL - 37

SP - 116

EP - 127

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 1

ER -